Analyst Conference Call Summary

Cantel Medical

conference date: December 5, 2013 @ 8:00 AM Pacific Time
for quarter ending: October 30, 2013 (Q1, first quarter fiscal 2014)

Forward-looking statements


Basic data (GAAP):

Revenue was , % sequentially from $114.0 million

Net income was , % sequentially from $10.2 million

EPS (earnings per share) were , % sequentially from $0.25


No specific guidance (Cantel never has provided specific guidance).

Conference Highlights:


Realigning reporting segments were changed, adding some formerly "other" revenue to Water Purification/Mar Cor segment.

Endoscopy segment revenue was a record , sequentially from $44.5 million, and up % y/y.

Healthcare Disposables (Crosstex and SPS) sales were up

Water Purification and Filtration segment (Mar Cor) revenue was $ million, %sequential.y from $35.7 million, and up % y/y.

Therapeutic Filtration (formerly Dialysis) segment sales % y/y.

% gross margin, sequentially from 43.1%

Cash and equivalents balance ended at , sequentially from $34.1 million. Debt ended at $ million. Cash flow from operations $ million. Cap ex $ million.

EBITDAS was $, sequentially from $21.6 million and up from $ million year-earlier.

Cost of sales was $ million, leaving gross profit of $ million. Operating expenses were $ million consisting of: $ million selling; $ million general and administrative; $ million research and development. Interest expense $ million. Income taxes $ million.




OpenIcon Analyst Conference Summaries Main Page


More Analyst Conference Pages:



Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2013 William P. Meyers